Thursday 16 October, 2025
Objectives: Docetaxel is a commonly used anti-cancer drug. Due to higher incidence of severe neutropenia in patients with impaired liver…
Read morePoster: Applications- Oncology
A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model
Thursday 16 October, 2025
PDF of poster Objectives: The previously developed semi-mechanistic pharmacokinetic-pharmacodynamic model for the time course of docetaxel induced myelosuppression [1] was…
Read moreA Novel PKPD Model to Describe the Interaction of Drug Response of Combination Therapy: An Application in Preclinical Oncology.
Thursday 16 October, 2025
Objectives: Combination drug therapy clinical trials, especially in the field of oncology, are extremely prevalent. In order to evaluate the…
Read moreSemi-Mechanistic Modelling of the Tumour Growth Inhibitory Effects of a New Anti-angiogenic Drug.
Thursday 16 October, 2025
Objectives: To develop a mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for a new antiangiogenic drug using human xenografts. Methods: Experimental. Human xenografts…
Read morePharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity
Thursday 16 October, 2025
PDF of poster Introduction and objectives: The anticancer agent indisulam is metabolized by the cytochrome P450 enzymes CYP2C9 and CYP2C19….
Read morePopulation pharmacokinetic study of methotrexate in patient with lymphoid malignancy
Thursday 16 October, 2025
Objectives: A population pharmacokinetic model was developed to describe dose-exposure relationships of methotrexate (MTX) in adults with lymphoid malignancy; this…
Read moreSemi-mechanistic PKPD model for neutropenia using K-PD model in patients receiving high dose of chemotherapy
Thursday 16 October, 2025
Background and Objectives: High dose chemotherapy (HDC) treatment has been used widely as adjuvant therapy in several types of cancer…
Read morePopulation Pharmacokinetics of Aplidin® (plitidepsin) in Subjects with Cancer
Thursday 16 October, 2025
Background and Objectives: Aplidin® (plitidepsin) is a cyclic depsipeptide compound isolated from Aplidium albicans that was shown to inhibit protein…
Read morePopulation PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects
Thursday 16 October, 2025
Background: Neutropenia was the trabectedin (Yondelis®, ET-743) dose limiting toxicity in phase I studies. The objective of the present study…
Read moreModel Based Neutrophil Guided Dose Adaptation in Chemotherapy
Thursday 16 October, 2025
Objectives: Severe neutropenia is one of the most important dose limiting events in many anticancer regimens. One of the most…
Read more